3 industry case studies
Merck, AbbVie, and Promega on DEL screens, PROTAC degraders, ternary-complex formation, and BRET/HiBiT readouts.
White Paper
Beyond Permeability: A New Era of Drug Discovery
If you're working on PROTAC discovery, peptide therapeutics, target engagement assays, or DEL screening, you've hit the same wall everyone else has: some of your biologically interesting molecules(DELs, macrocycles, PROTACs, oligos, large peptides) can't get into live cells.
The Portal platform enables you to deliver impermeable molecules directly into live cells, at scale in 96- or 384-well formats, so you can do real biology on day one — not month nine.
Get the PDF
DEL + PROTAC + macrocycle delivery
~125,000 DEL molecules per cell, R²=0.93 dose-proportional in PBMCs, full dose-response on Galaxy-i HTS dispensers.
Skip MedChem permeability work
Bypass the 6–12 months and $500K–$1M+ of MedChem optimization before you know the biology is real.
Beyond Permeability: A New Era of Drug Discovery
If you're working on PROTAC discovery, peptide therapeutics, target engagement assays, or DEL screening, you've hit the same wall everyone else has: some of your biologically interesting molecules(DELs, macrocycles, PROTACs, oligos, large peptides) can't get into live cells.
The Portal platform enables you to deliver impermeable molecules directly into live cells, at scale in 96- or 384-well formats, so you can do real biology on day one — not month nine.